MYC and hepatocellular carcinoma: In an established HCC patient-derived xenograft (PDX) model with positive expression of MYC and SCARB2 (Fig. 7d, e), we observed that PMB suppressed the tumor growth and the combination of PMB and sorafenib further decreased the growth and weights of PDXs in mice (Fig. 7f–h).